Refractory
leukemia remains the most common therapeutic problem in clinical treatment of
leukemia. The key therapy of refractory
leukemia is to kill, thoroughly, the minimal residual disease and
leukemia stem cells in the highly vascularized red marrow ...
[Published Molecular Pharmaceutics - May 21 2013]